[{"address1": "Gooimeer 2-35", "city": "Naarden", "zip": "1411 DC", "country": "Netherlands", "phone": "31 35 206 2971", "website": "https://www.newamsterdampharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.", "fullTimeEmployees": 62, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Harvey Davidson FACC, Facp., M.D.", "age": 68, "title": "CEO, President, Executive Board Member & Director", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 885600, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.", "age": 70, "title": "Founder, Chief Scientific Officer, Member of Executive Board & Director", "yearBorn": 1954, "fiscalYear": 2023, "totalPay": 677758, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mayur Amrat Somaiya", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 402304, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Juliette  Audet M.B.A., M.Sc.", "age": 37, "title": "Chief Business Officer", "yearBorn": 1987, "fiscalYear": 2023, "totalPay": 45625, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Douglas F. Kling", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Louise  Kooij", "age": 48, "title": "Chief Accounting Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Philippe", "title": "Executive VP &Head of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  Rambo", "title": "Executive Vice President of Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maryellen  McQuade", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Ditmarsch M.D.", "age": 57, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 19.0, "open": 19.21, "dayLow": 18.34, "dayHigh": 19.21, "regularMarketPreviousClose": 19.0, "regularMarketOpen": 19.21, "regularMarketDayLow": 18.34, "regularMarketDayHigh": 19.21, "payoutRatio": 0.0, "beta": -0.056, "forwardPE": -9.801587, "volume": 434131, "regularMarketVolume": 434121, "averageVolume": 855052, "averageVolume10days": 514170, "averageDailyVolume10Day": 514170, "bid": 18.5, "ask": 18.57, "bidSize": 1, "askSize": 1, "marketCap": 1983156736, "fiftyTwoWeekLow": 15.19, "fiftyTwoWeekHigh": 27.29, "priceToSalesTrailing12Months": 59.033062, "fiftyDayAverage": 23.1568, "twoHundredDayAverage": 19.844425, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1333108608, "profitMargins": 0.0, "floatShares": 43936873, "sharesOutstanding": 107053000, "sharesShort": 2798784, "sharesShortPriorMonth": 2967626, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.026099999, "heldPercentInsiders": 0.00408, "heldPercentInstitutions": 1.01738, "shortRatio": 3.98, "shortPercentOfFloat": 0.0398, "impliedSharesOutstanding": 107053000, "bookValue": 4.111, "priceToBook": 4.5062027, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -198916000, "trailingEps": -2.21, "forwardEps": -1.89, "enterpriseToRevenue": 39.683, "enterpriseToEbitda": -7.243, "52WeekChange": -0.17891097, "SandP52WeekChange": 0.2021538, "quoteType": "EQUITY", "currentPrice": 18.525, "targetHighPrice": 52.77778, "targetLowPrice": 35.59008, "targetMeanPrice": 44.538376, "targetMedianPrice": 45.807705, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 422728992, "totalCashPerShare": 4.576, "ebitda": -184059008, "totalDebt": 506000, "quickRatio": 10.371, "currentRatio": 10.614, "totalRevenue": 33594000, "debtToEquity": 0.134, "revenuePerShare": 0.373, "returnOnAssets": -0.29273, "returnOnEquity": -0.47369, "grossProfits": 33594000, "freeCashflow": -108734752, "operatingCashflow": -154156992, "revenueGrowth": 8.898, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -0.85888, "financialCurrency": "USD", "symbol": "NAMS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -2.500002, "regularMarketPrice": 18.525, "marketState": "REGULAR", "corporateActions": [], "regularMarketTime": 1740171201, "exchange": "NGM", "messageBoardId": "finmb_685404834", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "shortName": "NewAmsterdam Pharma Company N.V", "longName": "NewAmsterdam Pharma Company N.V.", "fiftyDayAverageChange": -4.6317997, "fiftyDayAverageChangePercent": -0.20001899, "twoHundredDayAverageChange": -1.3194256, "twoHundredDayAverageChangePercent": -0.066488475, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2022-11-23", "prevName": "Frazier Lifesciences Acquisition Corporation", "nameChangeDate": "2025-02-21", "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612881000000, "regularMarketChange": -0.47500038, "regularMarketDayRange": "18.34 - 19.21", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 855052, "fiftyTwoWeekLowChange": 3.335, "fiftyTwoWeekLowChangePercent": 0.21955235, "fiftyTwoWeekRange": "15.19 - 27.29", "fiftyTwoWeekHighChange": -8.765001, "fiftyTwoWeekHighChangePercent": -0.32117996, "fiftyTwoWeekChangePercent": -17.891098, "epsTrailingTwelveMonths": -2.21, "epsForward": -1.89, "epsCurrentYear": -1.9845, "priceEpsCurrentYear": -9.334845, "displayName": "NewAmsterdam Pharma Company", "trailingPegRatio": null, "__fetch_time": "2025-02-21"}]